[PRESS RELEASE — LONDON, UK, 9 May, 2024] — The UK is the primary driver of new growth in Europe’s medical cannabis market, with sales of medical cannabis greater than expected due to ‘unusually high’ consumption volumes on a per-patient basis.

By the end of 2024, for example, 62,960 patients are forecasted to be using medical cannabis in the UK, generating €240 million (£205 million) in sales, meaning the average medical cannabis patient in the UK will consume €3,811-worth (£3,261) of medical cannabis per year, or €318-worth (£272) per month.

Compare this to Germany, with the largest medical cannabis market and patient population in Europe, where the average medical cannabis patient will consume €1,563 (£1,342) of medical cannabis per year, or €130 (£112) per month.

Average prices paid per gram of dried medical cannabis flower or millilitre of oil are lower in the UK than in Germany, so the primary factor contributing to this staggering 144% difference in spend is an even larger divergence in consumption volumes.

These findings have been published today in a new report from UK-based cannabis data and intelligence company, Prohibition Partners.

Why So High?
Speaking about the potential reasons for the high consumption rates in the UK compared to other European countries, Lawrence Purkiss, senior analyst at Prohibition Partners, said: “The comparatively high per-patient consumption rates in the UK are at least in part a consequence of the fact that the market is entirely private and self-paid. The financial incentives within the system are geared towards high prescription volumes, unlike in Germany where at least 50% of patients have their medical cannabis costs reimbursed under public healthcare.”

Stephen Murphy, co-founder and CEO of Prohibition Partners, added: “The findings in the 9th Edition of ‘The European Cannabis Report’ highlight an intriguing trend: Patients in the UK are consuming more than their counterparts in other European markets. Since the legalisation of medical cannabis in 2018, private companies have aimed to enhance options and accessibility for patients. However, due to supply chain restrictions and costs, patients often opt for volume over frequency. This underscores the need for continued efforts to streamline regulations and improve affordability to ensure patients’ needs are adequately met.”

UK Market & Patient Explosion
Growth in the total number of medical cannabis patients in the UK is also forecast to soar over the next four years. By 2028, the number of medical cannabis patients in the UK is expected to increase by 124% to approximately 141,000 patients (up from approx. 63,000 by the end of 2024).

By comparison, in Germany the growth rate is just 24%, with approximately 346,000 medical cannabis patients anticipated by 2028 (up from approx. 278,000 by the end of 2024).

Together, Germany and the UK will account for 77% of all medical cannabis sales and patients in Europe by 2028 (Germany 50%, UK 27%).

Private Clinics Driving Growth
Although medical cannabis was legalised in the UK in November 2018 and is technically available on prescription through the National Health Service (NHS), patient access to medical cannabis in the UK is almost exclusively facilitated by private clinics.

These clinics are supplied by large medical cannabis distributors like Curaleaf Laboratories. Of the growth in sales and patient population in the UK, Jonathan Hodgson, CEO of Curaleaf Laboratories, said: “The beginning of 2024 has already shown a tremendous level of growth, with a record number of UK private clinics now providing medical cannabis treatment for lower appointment costs than ever before. More formulations and dosage forms have entered the market, such as pastilles and liquid vape cartridges, broadening the treatment options available for specialists to prescribe for patients.”

These medical cannabis findings have been published today in a new report – “The European Cannabis Report: 9th Edition” – by UK-based cannabis data and intelligence firm, Prohibition Partners. A version of the report is now available to download for free via the Prohibition Partners website.

ABOUT PROHIBITION PARTNERS
Prohibition Partners is a data, media and tech company operating in the fast-growing legal cannabis industry. We provide the industry with specialist information and data analytics.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

CannMart moves to direct-to-retailer distribution in the province of Saskatchewan and reports in-house brand Roilty continues to drive growth in concentrate categories, with product breadth expansion from Rilaxe Cannabis

TORONTO, Aug. 24, 2023 (GLOBE NEWSWIRE) — Lifeist Wellness Inc. (“Lifeist” or the “Company”) (TSXV: LFST) (FRANKFURT: M5B) (OTCMKTS: LFSWF), a health-tech company that leverages advancements in science and technology to build breakthrough companies that transform human wellness, today highlighted the continued strength of CannMart Inc.’s (“CannMart”) in-house cannabis concentrate brand Roilty, the expansion of Rilaxe Cannabis in multiple provinces across Canada, and the strategic move to direct-to-retailer distribution in the province of Saskatchewan.

“As we navigate the competitive landscape of the cannabis industry, I am pleased to highlight the recent progress of CannMart including the continued growth of our in-house brand Roilty and Rilaxe product lines,” said Daniel Stern, CEO of CannMart. “Roilty’s growth in the cannabis concentrate market underscores our commitment to delivering exceptional products that resonate with consumers. The strategic expansion of Rilaxe from dried fruit edibles to include soft-chews and pre-roll blunts demonstrates our dedication to innovation and addressing diverse consumer preferences. Our recent strategic move to direct-to-retailer distribution in Saskatchewan has not only streamlined our distribution process but will lead to improved margins. Through the strategic allocation of our marketing and sales resources we are generating growth in a very competitive line of business. Our commitment to budtender education, active engagement, and fostering collaborative relationships with diverse retail partners is making a difference and critical to achieving long-term profitability.”

Roilty’s year-over-year growth has been impressive, starting from a dozen products in June 2022 and growing to over 35 SKUs by Q3 2023. A large portion of SKU expansion has been through the Ontario Cannabis Store with multi-pack offerings in the province’s flow-through model selling well above the key performance indicators set by the province. With 55% market penetration across Canada and a 10% increase in points of distribution in the last 30 days, Roilty has captured more market share in the concentrate category experiencing a 70% year-over-year increase in units sold for all of Canada, led by Ontario with an 83% increase and Alberta with 56% increase in units sold.⁽¹⁾

Rilaxe has also experienced substantial growth, development, and innovation, with expanded offerings tailored to each province’s customer demand and needs. These product enhancements and expansions have been influenced by real-time feedback from provincial boards, retailers, and end-use consumers. Most notably, the addition of Rilaxe Berri Blunts (3 x 0.7G), as a general list SKU in the fast-growing pre-roll categories, have sold over 13,000 units since the product launched in January 2023. Additional success has come from the launch of nostalgic sour-soft chews: Rilaxe Sour Cherry 1:1 and Rilaxe Sour Peach 1:1 gummies, which launched in June 2023 and sold through the initial inventory within the first 2 weeks. With the introduction of new products, Rilaxe’s store penetration has grown 51% in the last 30 days.⁽¹⁾

CannMart has expanded its efforts in Saskatchewan, moving to a direct-to-retailer model creating unique sales opportunities to leverage a full portfolio of concentrates, infused pre-rolls and edibles. Owning and managing retailer relationships, which allows for more control over product launches, lifecycle management, and inventory controls, create more nimble pricing and distribution for enhanced customer experience.

(1) Data Source: 3^rd party cannabis data and internal sales data.

About Lifeist Wellness Inc.

Sitting at the forefront of the post-pandemic wellness revolution, Lifeist leverages advancements in science and technology to build breakthrough companies that transform human wellness. Portfolio business units include: CannMart, which operates a B2B wholesale distribution business facilitating recreational cannabis sales to Canadian provincial government control boards including for CannMart Labs, a BHO extraction facility producing high margin cannabis 2.0 products; Australian Vapes, one of Australia’s largest online retailers of vaporizers and accessories; and Mikra, a biosciences and consumer wellness company developing and selling innovative therapies for cellular health.

Information on Lifeist and its businesses can be accessed through the links below:

www.lifeist.com
https://cannmart.com
https://www.roilty.co
https://wearemikra.com/
www.australianvaporizers.com.au

Contact:

Meni Morim, Lifeist Wellness Inc., CEO
Ph: 647-362-0390
Email: ir@lifeist.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release or has in any way approved or disapproved of the contents of this press release.

Forward Looking Information

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not historical in nature contain forward-looking information. Forward-looking information can be identified by words or phrases such as “may”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen.

The forward-looking information contained herein, including, without limitation, statements related to expectations of improved margins as a result of direct-to-retailer distribution in Saskatchewan , are made as of the date of this news release and is based on assumptions management believed to be reasonable at the time such statements were made, including without limitation, expectations that the streamlining of its distribution channel in Saskatchewan will reduce expenses and increase margins. While we consider these assumptions to be reasonable based on information currently available to management, there is no assurance that such expectations will prove to be correct. By its nature, forward-looking information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this news release. Such factors include, without limitation: the failure to realize the expected benefits from direct-to-retailer distribution in Saskatchewan, and risks relating to the Company’s ability to execute its business strategy and the benefits realizable therefrom. Additional risk factors can also be found in the Company’s current MD&A filed under the Company’s SEDAR profile at www.sedar.com. Readers are cautioned not to put undue reliance on forward-looking information. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

Source: Lifeist Wellness Inc.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as “expects”, “will”, “anticipates”, and “estimates”; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief “snapshot” of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled “Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

The company’s first-ever acquisition adds a new category to its Nevada portfolio, signaling a new phase of growth and expansion

LOS ANGELES, June 08, 2023 (GLOBE NEWSWIRE) — Sunderstorm, an award-winning company in the consumer cannabis space, has acquired Nevada-based Abide Brands, maker of Bounti Vapes. The acquisition allows Sunderstorm to add valuable team members and a new product category to its Nevada portfolio. This is the first acquisition for the California-based company, and it marks the start of a new phase of growth that will include expanding its categories nationally.

Sunderstorm, which started the year with one of its best quarters to date, continues to enjoy sales growth built on a foundation of great systems, automation, products and team building. These investments in ready-to-scale infrastructure put the company in a position to accelerate growth, and Sunderstorm initiated its expansion phase with the acquisition of Abide Brands, a respected vape company with a reputation for quality products and talented leadership.

“We’ve built this machine to scale and last, and we’re ready to leverage it for future growth,” says Cameron Clarke, Co-Founder and CEO of Sunderstorm. “By bringing Abide Brands into the fold, we’re adding a new product category and accomplished team members to our expanding Nevada presence. This is the first of more big moves to come.”

“Sunderstorm is a great partner for all we want to accomplish with Bounti Vapes,” adds Kevin Spence, President and CEO of Abide Brands. “The synergy between our teams will strengthen all we do and position us both for greater success.”

Nevada represents a billion dollar cannabis market that’s widely expected to grow in coming years. Sunderstorm has a strong presence in the Nevada market with KANHA, its award-winning premium gummies brand, and Abide Brands will add to its statewide market share.

About Sunderstorm
Sunderstorm is one of the largest and most trusted companies in the consumer cannabis space. Inspired by passion for science and plant medicine, Sunderstorm prides itself on zero pesticides, all-natural ingredients and precision dosage that earned the Most Accurately Formulated Edible award at The Cannys. Sunderstorm’s brands include KANHA, the fourth-largest U.S. edible brand, featuring the best-tasting flavors and a NANO series with the only proven fast-acting technology. Established in California in 2015, Sunderstorm serves California, Nevada, Massachusetts, Colorado and will enter the Asian market this year as one of the first U.S. brands in Thailand. The lifestyle-driven company strives to elevate the experiences that consumers love, from music and action sports to wellness and yoga, in pursuit of greater exploration.

About Abide Brands
Nevada-based Abide Brands is the maker of Bounti Vapes, one of the top-selling vape brands in the state. Bounti, a boutique craft brand, was introduced by Las Vegas natives as a contrast to the low-quality products flooding the market. Their artisanal blends quickly gained a loyal base of discerning consumers. As part of Sunderstorm, Abide Brands is now positioned to meet the growing demand from its customers.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

• Flora generated $37.2 million in revenue in FY2022, a 314% increase YoY
• Record Q4 2022 revenue increased to $11.5 million, a 7% sequential increase from Q3 2022
• Gross profit for FY2022 increased by 494%, from $2.4 million to $14.4 million YoY
• Company reaffirms its 2023 revenue guidance to range between $90 million – $105 million
• Flora management to host a webcast Monday, April 3, at 8:00 am ET

FORT LAUDERDALE, Fla., March 31, 2023–(BUSINESS WIRE)–Flora Growth Corp. (NASDAQ: FLGC) (“Flora” or the “Company”), a leading cultivator, manufacturer and distributor of global cannabis products and brands, reported today its financial and operating results for the fiscal year ended December 31, 2022. All financial information is provided in U.S. dollars unless indicated otherwise.

“In 2022, we not only met our revenue guidance but reported both quarterly and annual record revenue. This accomplishment was thanks to the successful completion and integration of our M&A transactions, the compelling value proposition of our products in our House of Brands and the operational milestones we achieved throughout the year,” said Luis Merchan, Chairman and CEO of Flora. “It is important to note that we have accomplished all this despite having to navigate one of the most hostile business environments to date, especially for the cannabis industry. Nonetheless, we achieved both quarterly and annual record revenue, improved margins and increased our gross profits – all while cutting costs and improving operational efficiencies.”

“Today, I remain more confident than ever in Flora’s opportunity to not only be one of the largest players in the international cannabis industry but to change the global landscape of cannabis. I am proud to reaffirm the 2023 revenue guidance we shared earlier in the year of between $90 million and $105 million,” Merchan added.

FY2022 Financial Highlights

• For the FY2022, Flora generated $37.2 million in revenue, a 314% increase year-over-year. This was primarily driven by the House of Brands businesses. Additionally, in Q4 2022, revenue was $11.5 million, a 7% sequential increase from Q3 2022, driven primarily by organic growth.
• Gross profit for FY2022 increased by 494% year-over-year to $14.4 million.
• Gross margin improved year-over-year from 27% in FY2021 to 39% FY2022.
• Adjusted EBITDA loss for FY2022 was $18.3 million, up from $16.5 million in FY2021.
• Adjusted EBITDA margin for FY2022 improved to -49.3% from -184.2% in FY2021.
• Net loss for FY2022 was $52.6 million as compared to $21.4 million for FY2021 and net loss margin for FY2022 improved to -141.6% from -237.9% in FY2021.
• FY2022 capex decreased to $1.3 million from $4 million in the prior year. This decrease was primarily driven by the completion of larger projects in 2021, such as the build-out of the Company’s Colombian cannabis production facility, Cosechemos, while 2022 capital expenditures included smaller-scale projects focused on realizing operations at Cosechemos and Flora’s labs.
• Operating expenses for FY2022 were $67.7 million, of which almost half were due to non-cash charges, including an impairment charge of $26.2 million as well as depreciation and amortization, purchase price allocation, and share-based compensation charges.
• As a percentage of sales, operating expenses for 2022 decreased from 239% in FY2021 to 182% in FY2022.
• As of December 31, 2022, the Company had approximately $9.5 million in cash and cash equivalents as compared to $37.6 million as of December 31, 2021.

Adjusted EBITDA loss and Adjusted EBITDA margin are non-U.S. GAAP figures. A reconciliation of U.S. GAAP to non-U.S. GAAP financial measures has been provided in the section titled “About Non-GAAP Financial Measures”. Important disclosures regarding the use of non-U.S. GAAP supplemental financial measures are also included below.

2023 Outlook

• Flora’s 2023 revenue guidance of $90 million to $105 million reflects expected organic growth in the House of Brands division and expansion of the Commercial and Wholesale division’s capabilities.
• House of Brands and Commercial and Wholesale divisions expect roughly equal contributions to total revenue, while the Pharmaceutical division is expected to contribute up to 10% of total revenue.
• Flora continues to evaluate future M&A transactions that align with the goal of creating one of the world’s largest end-to-end cannabis supply chains.
• The Company furthered its commitment to organizational and financial efficiencies, implementing internal cost controls and focusing on high-margin revenue generation.

Recent Operational Highlights

• Acquired Franchise Global Health (FGH), an international cannabis company with primary operations in Germany.
• Flora’s House of Brands saw an increase in customer base to approximately 500,000 consumers and expanded distribution to over 14,000 doors.
• Became a domestic reporter with respect to Securities and Exchange Commission (the “SEC”) filings under the Exchange Act of 1934, as amended (the “Exchange Act”) and transitioned to financial reporting under U.S. Generally Accepted Accounting Principles (“U.S. GAAP”).
• JustCBD achieved record-breaking sales during the Black Friday Sales Event in 2022, making it the most successful sales event in the Company’s history.
• Completed construction of Bogota, Colombia-based Flora Lab 4, a laboratory specializing in prescription cannabis formulations.
• As a result of the FGH acquisition, Flora appointed former FGH CEO Clifford Starke as President of Flora and member of the Board of Directors and former FGH Chief Operating Officer Edward Woo as a member of the Board of Directors.
• Completed its first extraction of CBD isolate through Flora Lab 1, and successful importation to the United States.
• Received 2022 export quota from the Colombian government for 43,600kg of high-THC cannabis.
• Colombian government released regulations allowing for THC export, with export to partners beginning in Q4 2022 – broadening the Company’s opportunity for international export.
• Awarded best M&A transaction at Benzinga Capital Conference for the acquisition of JustBrands.

Earnings Call: April 3, 2023, at 8:00AM ET

Live Webcast Details

Date: Monday, April 3, 2023

Time: 8:00 a.m. ET

Online Participant Link: https://us02web.zoom.us/webinar/register/WN_Y0I1RwIISN6Y2sn8I5QEYQ

After registering, you will receive a confirmation email containing information about joining the webinar.

The live webcast will be available online through the above participant link and will be archived and available on the investor page of the Company’s website within approximately 24 hours, until April 2024.

About Flora Growth Corp.

Flora Growth Corp. is a global cannabis company dedicated to bringing the benefits of cannabis to people worldwide. Our commitment is to create, master and connect the international cannabis supply chain by setting the standard for world-class cultivation and manufacturing, thoughtful brand development, and rigorous research and development of medical-grade cannabis products that meet the highest standards of quality, safety, and efficacy. Our mission is to create a world where the benefits of cannabis are accessible to everyone, and we are working toward that goal by becoming a leading importer and exporter of cannabis to meet demand in every corner of the market. Visit www.floragrowth.com or follow @floragrowthcorp on social media for more information.

Cautionary Statement Concerning Forward-Looking Statements

This press release contains ‘‘forward-looking statements,’’ as defined by federal securities laws. Forward-looking statements reflect Flora’s current expectations and projections about future events at the time, and thus involve uncertainty and risk. The words “believe,” “expect,” “anticipate,” “will,” “could,” “would,” “should,” “may,” “plan,” “estimate,” “intend,” “predict,” “potential,” “continue,” and the negatives of these words and other similar expressions generally identify forward looking statements. Such forward-looking statements are subject to various risks and uncertainties, including those described under the section entitled “Risk Factors” in Flora’s Annual Report on Form 10-K for year ended December 31, 2022 filed with the SEC on March 31, 2023, as such factors may be updated from time to time in Flora’s periodic filings with the SEC, which are accessible on the SEC’s website at www.sec.gov and under the Company’s SEDAR profile at www.sedar.com. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in Flora’s filings with the SEC. While forward-looking statements reflect Flora’s good faith beliefs, they are not guarantees of future performance. Flora disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, new information, data or methods, future events or other changes after the date of this press release, except as required by applicable law. You should not place undue reliance on any forward-looking statements, which are based only on information currently available to Flora (or to third parties making the forward-looking statements).

About Non–U.S. GAAP Measures

Adjusted EBITDA is a non-U.S. GAAP financial measure that does not have any standardized meaning prescribed by U.S. GAAP and may not be comparable to similar measures presented by other companies. We calculate Adjusted EBITDA as total net loss, plus (minus) income taxes (benefit), plus (minus) interest expense (income), plus depreciation and amortization, plus (minus) non-operating expense (income), plus share based compensation expense, plus goodwill and other asset impairment charges, plus (minus) unrealized loss (gains) from changes in fair value, plus charges related to the flow-through of inventory step-up on business combinations, plus other acquisition and transaction costs. Management believes that Adjusted EBTIDA provides meaningful and useful financial information as this measure demonstrates the operating performance of the business.

Adjusted EBITDA margin % is a non-U.S. GAAP financial measure that does not have any standardized meaning prescribed by U.S. GAAP and may not be comparable to similar measures presented by other companies. We calculate Adjusted EBITDA margin % as Adjusted EBITDA, as described above, divided by revenue for the period.

The reconciliation of the Company’s Adjusted EBITDA, a non-U.S. GAAP financial measure, to net loss, the most directly comparable U.S. GAAP financial measure, for the year ended December 31, 2022 and 2021 is presented in the table below:

Management believes that this non-U.S. GAAP financial information is useful as a supplement to comparable U.S. GAAP financial information. Management reviews these non-U.S. GAAP financial measures on a regular basis and uses them, together with financial measures included in the Company’s financial statements, to evaluate and manage the performance of the Company’s operations. These measures should be evaluated in conjunction with the comparable U.S. GAAP financial numbers reported by the Company.

Table 1. Consolidated Statements of Financial Position

Table 2. Consolidated Statements of Loss and Comprehensive Loss

Table 3. Statement of Cash Flows

Table 4. Reconciliation of GAAP to non-U.S.GAAP financial results

Table 4

Reconciliation of GAAP to non-U.S.GAAP financial results

The reconciliation of the Company’s Adjusted EBITDA, a non-U.S. GAAP financial measure, to net loss, the most directly comparable U.S. GAAP financial measure, for the year ended December 31, 2022 and 2021 is presented in the table below: For a reconciliation of these non-U.S. GAAP financial measures to the most directly comparable U.S. GAAP financial measures, please see Table 4 under “Reconciliation of GAAP to non-U.S. GAAP financial results” included at the end of this release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230331005404/en/

Contacts

Investor Relations:
Investor Relations
ir@floragrowth.com

Public Relations:
Cassandra Dowell
+1 (858) 221-8001
flora@cmwmedia.com

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Toronto, ON – TheNewswire – March 1, 2023 – Hill Street Beverage Company Inc. (TSXV:HILL) (OTC:HSEEF) (“Hill Street” or the “Company”), a progressive bioscience implementation company that utilizes new technologies to provide innovative cannabis solutions and non-alcoholic beverage products globally, is pleased to announce the following updates from the three-month period ended December 31, 2022 (“Q2 FY 2023”) financial statements.

Continued DehydraTECH Expansions Lead to Record Quarterly Licensing Revenue & Growth

The Company continued to add states to its geographic footprint for DehydraTECH licensing as well as form factors to its portfolio of DehydraTECH-powered consumer products during the three-month period ended December 31, 2022.

As a result, the Company is pleased to announce that it grew DehydraTECH licensing revenues by 93% in Q2 versus the prior quarter and 263% for the fiscal year to date.

The following chart shows the DehydraTECH licensing revenues over the past 6 quarters:

The Transformed Vin(Zero) Business Model Leads to Record High Quarterly Revenue and Gross Profit

In Q2 FY 2023, Hill Street achieved record quarterly revenues overall and also for its Vin(Zero) alcohol-free beverage business.  The Vin(Zero) results were primarily driven by the Company’s new streamlined Vin(Zero) business model that created a new and different cadence to that business, as we have previously announced.   The Company now executes larger orders that are spread months apart to optimize the timing and efficiency of our supply chain.  The new business model significantly improves key financial metrics such as order to cash and reduced working capital in inventory, but the Vin(Zero) business must now be looked at across longer time frames to truly understand its patterns.

The following chart shows the Vin(Zero) alcohol-free business results over the past 6 quarters:

Release of Q2 FY2023 Financial Statements and MD&A

For the three-month period ended December 31, 2022, the Company has released its Financial Statements, and a comprehensive Company update by way of its Management Discussion and Analysis, which can now be found on the Company’s profile at www.sedar.com.

Craig Binkley, CEO comments: “This was by far the best quarterly result in the Company’s history, for both business units. We are very pleased that our December 31, 2022 results for the Vin(Zero) business validate that the fundamental adjustments we made to our business model over the past several months were well considered and on target.  By refocusing our efforts towards our two on-trend, strong-margin and streamlined business segments – Vin(Zero) beverage sales and DehydraTECH licensing – we are well positioned as we head into the spring.”

Hill Street Mailing List Launched

With the Company expecting increasing shareholder communication over the coming months, Hill Street is pleased to also announce that it has initiated an exclusive mailing list for all supporters wishing to receive direct and timely communication about Company updates.  If you wish to sign up for this mailing list, click HERE.

*All financial information is provided in Canadian dollars, is unaudited and subject to change.

About Hill Street Beverage Company Inc. (TSXV: HILL)

Hill Street is a progressive bioscience implementation company that utilizes new technologies to provide innovative cannabis solutions and non-alcoholic beverage products globally. We are pioneering the space where craft consumer products meet bioscience by leveraging our deep CPG expertise to commercialize leading-edge technologies to craft superior plant-derived consumer products. We are currently developing the platform for North American distribution around our rights to use Lexaria Bioscience Corp.’s ground-breaking DehydraTECH patent portfolio for product development, licensing and B2B sales of cannabis ingredients.

For more information on our business activities or to check out Hill Street’s award-winning alcohol-free line-up and order product to be delivered straight to your home go to www.hillstreetbeverages.com

For more information:

Matthew Jewell, Chief Financial Officer
matthew@hillstreetbevco.com

FORWARD-LOOKING STATEMENTS

Statements in this press release may contain forward-looking information. Any statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “would”, “anticipate”, “expects”, and similar expressions. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances, such as future availability of capital on favourable terms, may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement. The forward-looking statements contained in this press release are made as of the date of this press release. The Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise, except as required by securities law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

New Leadership Team is Focused on Accelerating Growth and Margin Enhancement

Highlights include:

• A new leadership team has been introduced with a focus on the following:
• Q2 saw a decrease in operating expenses of $2 million or 30% year over year and $3.5 million or 27% for the six months year over year in the North American accessories and Canada cannabis business. This is offset by increased costs of $4.4 million and $8.5 million relating to expanding the California cannabis distribution business for three and six months, respectively.
• Q2 saw continued growth of our California cannabis distribution business, generating revenue of a quarter-over-quarter increase of 177%.
• Q2 saw gross margin improve to 17.1% compared to 11.9% in Q1 2022. Our focus on driving efficiencies in our North American accessories business reduced overall inventory by 14% or $1.5 million. The team continues to focus on margin-enhancing products and opportunities.

TORONTO, Feb. 23, 2023 /PRNewswire/ – Humble & Fume Inc. (CSE: HMBL) (OTCQX: HUMBF) (“Humble” or the “Company”), a leading North American distributor of cannabis and cannabis accessories, today reported its second-quarter fiscal 2023 (“Q2 2023”) financial and operating results for the six and three months ended December 31, 2022.

“I want to acknowledge the effort made by our prior leadership team,” said CEO Jakob Ripshtein. “The past twelve months was a challenging adjustment period for our business.”

In Q2, the company saw a quarter-over-quarter revenue increase of 177% in its California cannabis distribution business. Operating expenses decreased by $2 million or 30% year over year in the North American accessories and Canada cannabis business and decreased by $3.5 million or 27% for the six months year over year. However, increased costs of $4.4 million and $8.5 million relating to expanding the California cannabis distribution business for three and six months, respectively, offset these savings.

“The progress we have made in addressing our inventory concerns is encouraging, but we are confident there is more we can do in this area,” said Mr. Ripshtein.

Gross margin improved to 17.1% compared to 11.9% in Q1 2022, thanks to driving efficiencies in the North American accessories business that reduced overall inventory by 14% or $1.5 million.

Mr. Ripshtein continued, “Our focus on margin-enhancing products and opportunities includes the introduction of a proactive, rigorous approach to address inventory levels further. We will concentrate on high-velocity, margin-enhancing SKUs, which are expected to provide working capital and gross profit benefits.”

The company’s new leadership team is focused on accelerating the growth of the cannabis business, driving change management to develop effective and efficient operations, margin enhancement within the North American accessories business, and prioritizing white-label offerings to deliver a differentiated service to customers that generate accretive margins.

Mr. Ripshtein concluded, “Our commitment to providing the best possible service to our customers goes hand in hand with ensuring that we are disciplined in addressing the task at hand inside our business. We must accelerate growth opportunities, drive efficiencies at every touchpoint, and deliver long-term shareholder value.”

The financial statements, notes to the financial statements, and Management’s Discussion and Analysis for the six and three months ended December 31, 2022, are available on the SEDAR website at www.sedar.com.

About Humble & Fume Inc.

Humble & Fume Inc. is a leading North American distributor of cannabis and cannabis accessories, supported by a customer-centric sales team and strong fulfillment infrastructure. As the only fully-integrated cannabis distribution solution, Humble bridges the gap for retailers, licensed cannabis producers, multi-state operators, and cannabis consumers to maximize sales penetration, and increase financial performance. With over 20 years of North American operating experience, Humble has cultivated extensive vendor and customer relationships, distributing premium cannabis consumables and consumption devices. The Company is comprised of subsidiaries that represents its vertical integration across North America: Humble+Fume, B.O.B. Headquarters Inc., Windship Trading LLC, Humble+ Cannabis Solutions and Fume Labs Inc.

Non-IFRS Financial Measures

EBITDA and Adjusted EBITDA are financial measures that are not defined under IFRS. We define EBITDA as net income (loss), or “earnings”, before interest, income taxes, depreciation and amortization. We define Adjusted EBITDA as EBITDA before: (i) fair value adjustments on biological assets and fair value adjustments on sale of inventory; (ii) share-based compensation expense; (iii) RTO listing expense; and (iv) goodwill impairment losses. We believe Adjusted EBITDA is a useful measure to assess the performance of the Company as it provides more meaningful operating results by excluding the effects of expenses that are not reflective of our operating business performance and other one-time or non- recurring expenses, and also provide additional perspective and insights when analyzing the core operating performance of the business. These supplemental non-IFRS financial measures should not be considered superior to, as a substitute for or as an alternative to, and should only be considered in conjunction with, the IFRS financial measures presented herein.

Forward-Looking Information and Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws relating to the proposed listing on the CSE, the focus of the Company’s business, and intentions of those subject to early warning disclosure requirements. Any such forward-looking statements may be identified by words such as “expects”, “anticipates”, “intends”, “contemplates”, “believes”, “projects”, “plans” and similar expressions. Readers are cautioned not to place undue reliance on forward-looking statements. Statements about, among other things, Humble & Fume Inc.’s strategic plans including future growth opportunities and strategies in the United States are all forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such forward-looking statements will occur as described herein. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances or actual results unless required by applicable law. Readers are encouraged to refer to the Company’s disclosure available on its SEDAR profile (at www.sedar.com) for information as to the risks and other factors which may effect the Company’s business objectives and strategic plans.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as “expects”, “will”, “anticipates”, and “estimates”; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief “snapshot” of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled “Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

In 2023, cannabis consumer taste will become more sophisticated as brands like Wana work to educate customers on the many potentials of the plant

Boulder, Colo. (December 22, 2022) – Wana Brands leadership predicts that the legal, regulated cannabis industry will expand its consumer base by investing in product innovation, including unique cannabinoid formulations to meet specific wellness needs. Product education will receive significant emphasis in 2023 as brands such as Wana seek to engage with consumers curious about the plant’s potential. However, lack of regulatory enforcement in new markets, such as New York, will pose an ongoing challenge to the cannabis industry in 2023.

Growing the consumer base

The popularity of the innovative Wana Quick Fast-Acting Gummies – which onset in approximately 15 minutes and offset in about three hours – has demonstrated that consumers are craving true innovation in infused cannabis products. Likewise, Wana Optimals – a line showcasing calibrated cannabinoid blends to address specific use cases like better sleep – has demonstrated that the maturing cannabis consumer is looking to manage their wellness needs with increasing precision. In 2023, Wana Brands will continue expanding its Optimals line, which currently includes Optimals Fit, Fast Asleep and Stay Asleep. In addition, reaching consumers through effective education will be critical to explaining the potential of cannabinoids beyond THC.

“Consumers will increasingly recognize the value of cannabis brands that meet specific needs and enable specific experiences rather than evaluating products purely on which ones have the highest level of THC for the lowest cost,” said Nancy Whiteman, CEO of Wana Brands. “The quality of the experience will drive brand choice as consumers become more experienced and discerning when assessing their cannabis options.  Ultimately, I think we will see consumers understanding that ‘value’ is about much more than low cost, high THC products.”

A competitive market will shine a light on quality

Even as Wana Brands works to achieve national recognition – adding four additional markets for a presence in 14 states, Puerto Rico and nine Canadian provinces – lack of federal guidance will remain a challenge. The cannabis industry must tackle a litany of regulations  – from marketing to banking – unlike any other CPG sector. Most urgently, companies such as Wana continue calling on Congress to pass SAFE Banking so the sector can function like any other regulated and taxed industry. However, the calls continue to fall on deaf ears in Washington, DC, with the likelihood of any helpful federal action unlikely in the foreseeable future.

Lack of regulatory enforcement in key states, such as New York, has allowed the illicit market to flourish while handcuffing legal, tax-paying operators. From bodegas to gifting stores, anybody who wants to sell cannabis illegally is doing just that, with none of the regulation or taxation that comes with being part of the legal market.

“As states like New York allow the illicit market flourish on every street corner, they are creating a bigger issue when the legal market comes online, setting up a situation where legal, safe, regulated brands will be behind from the beginning, adding the double whammy of lack of enforcement coupled with high taxation,” Whiteman said. “New York’s potency tax could add $6 per a hundred-milligram edible at retail. And that’s before you get into the cost of actually producing it. It’s untenable and it will make it much more difficult for legally produced brands to succeed.”

Standing with Community

In 2023, the cannabis industry will continue to provide unprecedented support in communities where the sector operates. Beyond simply tax revenues, the cannabis community has committed extensive resources to address some of the most challenging social issues. One example of this work will be the continued efforts of the Wana Brands Foundation, a $50 million charitable organization working to provide people with the resources they need to live happy, healthy lives. Established in 2022 by Whiteman with the proceeds of the sale of Wana to Canopy Growth Corp., the Wana Brands Foundation’s areas of focus include Research & Education, Food Security, Shelter, Safety, Mental Health, Sustainability, Community Connection and Social Justice.

With the prospect of publishing authoritative research on the potential of plant medicine, initial gifts included a $2 million gift to Johns Hopkins University Department of Psychiatry and Behavioral Sciences in support of cannabis and cannabinoid research, as well as a $1 million gift to the Johns Hopkins Center for Psychedelic and Consciousness Research, which focuses on how psychedelics affect behavior, mood, cognition, brain function, and biological markers of health. In 2023, these funds will be used to facilitate studies including the potential use of cannabinoids to treat autism and the effectiveness of psilocybin as a new therapy for opioid addiction, Alzheimer’s disease, post-traumatic stress disorder (PTSD), post-treatment Lyme disease syndrome (formerly known as chronic Lyme disease), anorexia nervosa and alcohol use in people with major depression.

A Bright Future

Despite the challenges, there are many bright spots for the cannabis industry. New states continue to legalize adult-use cannabis, with Missouri and Maryland poised to enact their recreational programs in 2023. Winning brands will look to grow the market through education rather than joining the race to the bottom in pricing. As consumer tastes mature, according to Whiteman and other leaders at Wana, they will recognize the power of the cannabis plant goes beyond intoxication. With access to more research, such as the work being conducted by the Johns Hopkins Cannabis lab, the industry can advance the understanding of the effective use of cannabis for a wide range of health and wellness benefits. These efforts will continue to reach wider audiences with more sophisticated formulations that allow people to achieve specific effects and experiences versus solely seeking the highest intoxication for the lowest cost possible.

For more information or to schedule an interview, please contact Shawna Seldon McGregor at 917-971-7852 or [email protected].

Wana Brands: Enhance Your Life

With North America’s largest distribution footprint, cannabis edibles producer Wana Brands is a top international brand available in 14 U.S. states, the U.S. territory of Puerto Rico and nine Canadian provinces and territories, generating close to $300 million in retail sales annually across more than 3,000 dispensaries. Through industry-leading innovation, Wana is developing cutting-edge use-case formulations and recipes, such as Wana Quick Fast-Acting Gummies, the top-selling quick-onset edible, and the Optimals Fast Asleep formulation. Wana is committed to the communities it serves by supporting more than 50 charitable organizations in the markets where the company operates. For more information or to subscribe to Wana’s e-newsletter, visit www.wanabrands.com. Follow Wana on LinkedIn, Twitter, YouTube and Pinterest. Subscribe to Wana’s Enhance Your Life Podcast.

###

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as “expects”, “will”, “anticipates”, and “estimates”; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief “snapshot” of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled “Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer